LGALS3 and non-small cell lung carcinoma: Additionally, our results revealed that the Galectin-3/KRAS/RalB/TBK1/NF-κB signaling pathway was activated by integrin αvβ3, leading to the EGFR-associated drugs resistance in NSCLC.